[go: up one dir, main page]

WO2008118754A3 - Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés - Google Patents

Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés Download PDF

Info

Publication number
WO2008118754A3
WO2008118754A3 PCT/US2008/057701 US2008057701W WO2008118754A3 WO 2008118754 A3 WO2008118754 A3 WO 2008118754A3 US 2008057701 W US2008057701 W US 2008057701W WO 2008118754 A3 WO2008118754 A3 WO 2008118754A3
Authority
WO
WIPO (PCT)
Prior art keywords
making
methods
gamma radiation
same
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/057701
Other languages
English (en)
Other versions
WO2008118754A2 (fr
Inventor
H. William Bosch
Janine Keller
Niels Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Priority to CA002680106A priority Critical patent/CA2680106A1/fr
Priority to EP08732593A priority patent/EP2139470A4/fr
Priority to JP2009554749A priority patent/JP2010522207A/ja
Publication of WO2008118754A2 publication Critical patent/WO2008118754A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008118754A3 publication Critical patent/WO2008118754A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions nanoparticulaires comprenant du docétaxel ou un sel, un dérivé, un conjugué ou analogue de celui-ci. Ces compositions subissent une stérilisation terminale par rayonnement gamma. L'invention concerne également des procédés de fabrication et d'utilisation de telles compositions.
PCT/US2008/057701 2007-03-23 2008-03-20 Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés Ceased WO2008118754A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002680106A CA2680106A1 (fr) 2007-03-23 2008-03-20 Compositions de docetaxel nanoparticulaires sterilisees par rayonnement gamma et procedes de fabrication associes
EP08732593A EP2139470A4 (fr) 2007-03-23 2008-03-20 Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés
JP2009554749A JP2010522207A (ja) 2007-03-23 2008-03-20 ガンマ照射滅菌ナノ粒子状ドセタキセル組成物および該組成物を作製するための方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89664707P 2007-03-23 2007-03-23
US60/896,647 2007-03-23

Publications (2)

Publication Number Publication Date
WO2008118754A2 WO2008118754A2 (fr) 2008-10-02
WO2008118754A3 true WO2008118754A3 (fr) 2009-12-30

Family

ID=39789241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/057701 Ceased WO2008118754A2 (fr) 2007-03-23 2008-03-20 Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés

Country Status (4)

Country Link
EP (1) EP2139470A4 (fr)
JP (1) JP2010522207A (fr)
CA (1) CA2680106A1 (fr)
WO (1) WO2008118754A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089544B2 (en) 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
EP2190413B1 (fr) * 2007-08-24 2015-01-28 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement des maladies néoplasiques
EP3167875A1 (fr) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire
CN102597168B (zh) 2009-11-04 2014-09-03 默克专利股份有限公司 用于液晶介质的化合物及其用于高频组件的用途
CN110799176A (zh) 2017-06-14 2020-02-14 克里蒂泰克公司 治疗肺部疾病的方法
EP3796951A4 (fr) * 2018-05-19 2021-07-07 Gary Binyamin Formulations de mousse et procédés d'administration au corps
CN114712316B (zh) * 2020-12-18 2023-10-20 江苏恒瑞医药股份有限公司 一种难溶性药物组合物及制备方法
US12083081B2 (en) * 2021-04-29 2024-09-10 Protara Therapeutics, Inc. Sterile aqueous choline salt compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248800B1 (en) * 1998-09-18 2001-06-19 Medlogic Global Corporation Methods for sterilizing cyanoacrylate compositions
US20020068092A1 (en) * 1999-10-08 2002-06-06 H. William Bosch Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20020086055A1 (en) * 1998-12-23 2002-07-04 Wong Patrick S. L. Controlled release liquid active agent formulation dosage forms
US6441253B1 (en) * 1997-08-21 2002-08-27 Florida State University Method for the synthesis of taxanes
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
US20020142050A1 (en) * 1999-05-27 2002-10-03 Acusphere Inc. Porous drug matrices and methods of manufacture thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
EP1855659A2 (fr) * 2005-02-24 2007-11-21 Elan Pharma International Limited Preparations de nanoparticules de docetaxel et de ses analogues

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441253B1 (en) * 1997-08-21 2002-08-27 Florida State University Method for the synthesis of taxanes
US6248800B1 (en) * 1998-09-18 2001-06-19 Medlogic Global Corporation Methods for sterilizing cyanoacrylate compositions
US20020086055A1 (en) * 1998-12-23 2002-07-04 Wong Patrick S. L. Controlled release liquid active agent formulation dosage forms
US20020142050A1 (en) * 1999-05-27 2002-10-03 Acusphere Inc. Porous drug matrices and methods of manufacture thereof
US20020068092A1 (en) * 1999-10-08 2002-06-06 H. William Bosch Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2139470A4 *

Also Published As

Publication number Publication date
EP2139470A2 (fr) 2010-01-06
WO2008118754A2 (fr) 2008-10-02
JP2010522207A (ja) 2010-07-01
CA2680106A1 (fr) 2008-10-02
EP2139470A4 (fr) 2010-07-28

Similar Documents

Publication Publication Date Title
WO2008118754A3 (fr) Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés
WO2008091835A3 (fr) Endoprothèses médicales implantables
EP2535058A3 (fr) Stabilisation de vaccins par lyophilisation
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
WO2008034013A3 (fr) Dispositifs médicaux et procédés de réalisation desdits dispositifs
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
EP2260835A3 (fr) Composition destinée a inhiber le proteasome
MX2010002179A (es) Composicion para el tratamiento de enfermedades neoplasicas.
WO2009099768A3 (fr) Revêtements biodégradables pour des dispositifs médicaux implantables
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
WO2008049116A3 (fr) Indoles substitués
WO2010104983A3 (fr) Dispositifs de liaison et de réparation de tissus biologiques et leurs méthodes d'utilisation. biological tissue connection and repair devices and methods of using same
MX2011012504A (es) Pirazinilpirazoles.
EP2710892A3 (fr) Utilisation de sarmentine et de ses analogues pour lutter contre les parasites des plantes
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL193024A0 (en) Levetiracetam formulations and methods for their manufacture
WO2007117687A3 (fr) Implants destines au traitement d'etats associes a la dopamine
WO2008027600A3 (fr) Compositions d'imatinib
EP2129672A4 (fr) Dérivés ester et carbamate d'azaadamantane et leurs procédés d'utilisation
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
IL186062A (en) Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
SI2231598T1 (sl) Novi derivati diazeniumdiolata postopek pripravele teh in njihovi farmacevtski sestavki
TW200833248A (en) Bisoximes as fungicides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08732593

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2680106

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009554749

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008732593

Country of ref document: EP